Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03637543

Recruitment Status : Active, not recruiting

First Posted : August 20, 2018

Last Update Posted : January 23, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Bristol-Myers Squibb

Dana-Farber Cancer Institute

Information provided by (Responsible Party):

David J. Einstein, Beth Israel Deaconess Medical Center

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	September 30, 2023
Estimated Study Completion Date :	March 31, 2025

To Top